Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 January 2025 | Story Gerda-Marie van Rooyen | Photo Supplied
KovsieX
KovsieX offers a comprehensive digital experience through podcasts, video content, and social media. This initiative is set to transform the student experience, creating a strong sense of belonging and collaboration across campuses.

Optimising student experience while providing students with multimedia training using state-of-the-art equipment and aligning with Vision 130, KovsieX is set to become a great asset to the university, its students, and the community. 

This initiative, approved by the UFS Rectorate on 29 November 2023, combines various student media brands on the Bloemfontein and Qwaqwa campuses (KovsieFM, Q-Lit, KovsieTV, KovsieCAST) into a unified brand consisting of three student-driven sub-departments. This includes audio (radio and podcasts), video (long and short form), and social media (including TikTok, Instagram, WhatsApp, and YouTube). 

An all-digital approach 

Gerben van Niekerk, Head of Student Experience (KovsieX), explains: “This all-digital approach leverages digital radio, podcasts, and social media platforms to create a sense of belonging among students by reflecting on and leading student life across the campuses.” KovsieX has achieved remarkable success, reaching an audience of more than 1,2 million in the first semester alone, with multiple TikTok videos surpassing 100 000 views. 

“Recognising the evolving radio landscape, our approach integrates a comprehensive digital strategy to adapt to changing media consumption preferences and provide students with hands-on experience on emerging platforms, strengthening their market relevance. KovsieX (previously KovsieFM) moves away from traditional FM broadcasting and has enabled the students to cover a wider range of topics that affect the Kovsie community,” says Van Niekerk. He adds, “The essence of KovsieX can be summarised in our one-word slogan: IMAGINE.”  

KovsieX supports Vision 130, as it leverages emerging technologies to enrich academic and non-academic student experiences. Furthermore, it also provides students with the opportunity to gain on-the-job and leadership experience in the KovsieX executive committee (KovsieXco), comprising a small group of ‘dynamic and highly talented students’, with their first objective: to decide on a brand name and setting on KovsieX – with the ‘X’ referring to experience. 

A mobile app provides students with easier access to KovsieX’s content. This initiative is set to increase students’ experience even more, as possible partnerships are in the pipeline to deliver a year-long dialogue series on themes pertinent to students. “This initiative will engage students on key issues such as leadership, mental health, heritage, and anti-discrimination through a blend of digital content – including interviews, social media posts, and expert discussions – and live on-campus events.”  

State-of-the-art facilities 

The construction of the KovsieX Pod on the Bloemfontein Campus allows students to produce content in a state-of-the-art podcast and video studio with Apple Mac workstations and a meeting room. A similar space in the current Student Media Building on the Qwaqwa Campus, named the KovsieX Q-Pod, is on the cards, as is the integration of KovsieX across the Bloemfontein and Qwaqwa campuses. “KovsieX will be broadcast from two locations and will, therefore, allow students from both campuses to interact with one another live on air. Both radio studios will be rebuilt to allow students to stream directly on YouTube, Instagram, and TikTok from both campuses simultaneously. This is made possible by cutting edge cloud-based software – popular in Europe – but KovsieX will be the first to leverage this technology in the country,” shares Van Niekerk.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept